S A Chambers1, S C Charman, A Rahman, D A Isenberg. 1. MRCP, The Centre for Rheumatology, University College London Hospital, 250 Euston Road, 3rd Floor Central, London NW1 2PG, UK. shrspk@aol.com
Abstract
OBJECTIVES: To determine the prevalence of other autoimmune diseases (AID) in black, Caucasian and South Asian patients with systemic lupus erythematosus (SLE) compared with the prevalence of these AID in the UK population, and to assess the impact of these additional AID on damage scores and mortality. METHODS: The prevalence and chronology of development of additional AID in SLE patients was determined by case note review. Comparisons were made with prevalence data for AID in the general UK population. The impact of additional AID on mortality and damage scores at up to 10 years was determined in the index cases (patients who developed another AID either in the same year or within 5 years of onset of SLE) compared with controls matched for sex, age, ethnicity and year of onset of SLE. RESULTS: There was no significant difference in the total number of AID that developed in patients from each ethnic group but differences in the frequency of some AID were noted. Mortality and damage scores were worse at 5 years in the study cases than the controls, particularly in the peripheral vascular category. CONCLUSION: Patients with SLE might develop other AID that could complicate management of SLE by having an adverse impact on damage scores and mortality.
OBJECTIVES: To determine the prevalence of other autoimmune diseases (AID) in black, Caucasian and South Asian patients with systemic lupus erythematosus (SLE) compared with the prevalence of these AID in the UK population, and to assess the impact of these additional AID on damage scores and mortality. METHODS: The prevalence and chronology of development of additional AID in SLEpatients was determined by case note review. Comparisons were made with prevalence data for AID in the general UK population. The impact of additional AID on mortality and damage scores at up to 10 years was determined in the index cases (patients who developed another AID either in the same year or within 5 years of onset of SLE) compared with controls matched for sex, age, ethnicity and year of onset of SLE. RESULTS: There was no significant difference in the total number of AID that developed in patients from each ethnic group but differences in the frequency of some AID were noted. Mortality and damage scores were worse at 5 years in the study cases than the controls, particularly in the peripheral vascular category. CONCLUSION:Patients with SLE might develop other AID that could complicate management of SLE by having an adverse impact on damage scores and mortality.
Authors: Ricard Cervera; Jean-Charles Piette; Josep Font; Munther A Khamashta; Yehuda Shoenfeld; María Teresa Camps; Soren Jacobsen; Gabriella Lakos; Angela Tincani; Irene Kontopoulou-Griva; Mauro Galeazzi; Pier Luigi Meroni; Ronald H W M Derksen; Philip G de Groot; Erika Gromnica-Ihle; Marta Baleva; Marta Mosca; Stefano Bombardieri; Frédéric Houssiau; Jean-Christophe Gris; Isabelle Quéré; Eric Hachulla; Carlos Vasconcelos; Beate Roch; Antonio Fernández-Nebro; Marie-Claire Boffa; Graham R V Hughes; Miguel Ingelmo Journal: Arthritis Rheum Date: 2002-04
Authors: Menelaos N Manoussakis; Chryssoula Georgopoulou; Elias Zintzaras; Marilyn Spyropoulou; Aikaterini Stavropoulou; Fotini N Skopouli; Haralampos M Moutsopoulos Journal: Arthritis Rheum Date: 2004-03
Authors: April M Jorge; Taotao Lao; Rachel Kim; Samantha Licciardi; Joseph El Khoury; Andrew D Luster; Terry K Means; Zaida G Ramirez-Ortiz Journal: J Immunol Date: 2022-01-26 Impact factor: 5.422
Authors: Murat Icen; Paulo J Nicola; Hilal Maradit-Kremers; Cynthia S Crowson; Terry M Therneau; Eric L Matteson; Sherine E Gabriel Journal: J Rheumatol Date: 2009-01 Impact factor: 4.666
Authors: Archana Sharma-Oates; Dawit T Zemedikun; Kanta Kumar; John A Reynolds; Avinash Jain; Karim Raza; John A Williams; Laura Bravo; Victor Roth Cardoso; Georgios Gkoutos; Krishnarajah Nirantharakumar; Janet M Lord Journal: BMC Med Date: 2022-10-13 Impact factor: 11.150